Government Accountability Office (GAO) Reports FDA Expertise is Needed to Develop AI Legislation
Summary
The FDA reported to the GAO that the FDA needs expanded authority to adequately regulate use of AI, in particular for medical devices enabled with AI. The GAO found that lawmakers need expertise from the FDA to develop legislation that would enhance oversight of AI. In turn, the GAO recommended that the FDA clearly identify, document and communicate its requested legislative changes to lawmakers.
Impacted Sectors
Additional Information
© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.